Second-line chemotherapy for prostate cancer: patient characteristics and survival - PubMed (original) (raw)
Second-line chemotherapy for prostate cancer: patient characteristics and survival
Kathleen W Beekman et al. Clin Prostate Cancer. 2005 Sep.
Abstract
Purpose: First-line chemotherapy with docetaxel in patients with progressive castrate metastatic prostate cancer has been shown to improve overall survival compared with mitoxantrone-based therapies. The use and outcomes of chemotherapy after first-line antimicrotubule-based therapy have not been well described.
Patients and methods: Patients with progressive castrate metastatic prostate cancer enrolled on an antimicrotubule-based protocol for treatment were followed to determine their baseline characteristics and outcomes with second- or third-line systemic therapy.
Results: Of 108 patients treated with antimicrotubule-based therapy, 81% received second-line therapy, and 40% received third-line therapies. Corresponding prostate-specific antigen (PSA) decreases > or = 50% were observed in 72%, 15%, and 22% of patients. Median survival times from the start of first-, second-, and third-line therapy were 21 months (95% confidence interval [CI], 18-25 months), 13 months (95% CI, 10-15 months) and 12 months (95% CI, 9-19 months). Significant prognostic indicators for survival in the second-line setting include pretreatment PSA level, alkaline phosphatase level, and performance status. Patients not fit to receive second-line therapy were more symptomatic with first-line therapy, as illustrated by a greater need for narcotic therapy (67% vs. 15%) and palliative radiation therapy after first-line therapy (57% vs. 10%) in lieu of second-line systemic therapy.
Conclusion: Eighty percent of patients received second-line chemotherapy, with a median survival of 12 months from the start of second-line treatment. Although only 40% received third-line chemotherapy, median survival was similar to that of patients in the second-line setting. Our data show that patients who initiate chemotherapy with symptoms are more likely to require palliative radiation therapy rather than chemotherapy as second-line therapy. A sequential or continuous administration of therapy may optimize the care of this subset of symptomatic patients.
Similar articles
- First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?
Michels J, Montemurro T, Murray N, Kollmannsberger C, Nguyen Chi K. Michels J, et al. Cancer. 2006 Mar 1;106(5):1041-6. doi: 10.1002/cncr.21695. Cancer. 2006. PMID: 16456811 Clinical Trial. - [What is the objective of second-line chemotherapy after failure of first-line chemotherapy in hormone-resistant metastatic prostate?].
El Demery M, Pouessel D, Avancès C, Iborra F, Rebillard X, Faix A, Ségui B, Delbos O, Ayuso D, Culine S. El Demery M, et al. Prog Urol. 2006 Jun;16(3):320-3. Prog Urol. 2006. PMID: 16821344 French. - Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, Gross M, Hutcheon D, Small EJ. Rosenberg JE, et al. Cancer. 2007 Aug 1;110(3):556-63. doi: 10.1002/cncr.22811. Cancer. 2007. PMID: 17577218 Clinical Trial. - Paclitaxel and docetaxel in prostate cancer.
Obasaju C, Hudes GR. Obasaju C, et al. Hematol Oncol Clin North Am. 2001 Jun;15(3):525-45. doi: 10.1016/s0889-8588(05)70230-6. Hematol Oncol Clin North Am. 2001. PMID: 11525295 Review. - Chemotherapy for hormone-refractory prostate cancer.
Shelley M, Harrison C, Coles B, Staffurth J, Wilt TJ, Mason MD. Shelley M, et al. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005247. doi: 10.1002/14651858.CD005247.pub2. Cochrane Database Syst Rev. 2006. PMID: 17054249 Review.
Cited by
- Inhibition of O-GlcNAc transferase sensitizes prostate cancer cells to docetaxel.
Xia M, Wang S, Qi Y, Long K, Li E, He L, Pan F, Guo Z, Hu Z. Xia M, et al. Front Oncol. 2022 Nov 10;12:993243. doi: 10.3389/fonc.2022.993243. eCollection 2022. Front Oncol. 2022. PMID: 36439421 Free PMC article. - Novel Treatment Strategy Using Second-Generation Androgen Receptor Inhibitors for Non-Metastatic Castration-Resistant Prostate Cancer.
Chung DY, Ha JS, Cho KS. Chung DY, et al. Biomedicines. 2021 Jun 9;9(6):661. doi: 10.3390/biomedicines9060661. Biomedicines. 2021. PMID: 34207755 Free PMC article. Review. - Combination of oncolytic adenovirus targeting SATB1 and docetaxel for the treatment of castration-resistant prostate cancer.
Mao L, Yu H, Ma S, Xu Z, Wei F, Yang C, Zheng J. Mao L, et al. J Cancer. 2021 Jan 25;12(6):1846-1852. doi: 10.7150/jca.46868. eCollection 2021. J Cancer. 2021. PMID: 33613773 Free PMC article. - A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer.
Rathkopf DE, Picus J, Hussain A, Ellard S, Chi KN, Nydam T, Allen-Freda E, Mishra KK, Porro MG, Scher HI, Wilding G. Rathkopf DE, et al. Cancer Chemother Pharmacol. 2013 Sep;72(3):537-44. doi: 10.1007/s00280-013-2224-8. Epub 2013 Jul 3. Cancer Chemother Pharmacol. 2013. PMID: 23820963 Free PMC article. Clinical Trial. - Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: an emerging initial radiation treatment option for organ-confined prostate cancer.
Hodges JC, Lotan Y, Boike TP, Benton R, Barrier A, Timmerman RD. Hodges JC, et al. J Oncol Pract. 2012 May;8(3 Suppl):e31s-7s. doi: 10.1200/JOP.2012.000548. J Oncol Pract. 2012. PMID: 22942832 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous